Tag Archives: Bernard Lachapelle

Drug Pipelines in Canada: Is There a Buyer for Future Innovation?

Last week, Canada‚Äôs National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how […]
Posted in Global, healthcare, IP, Market Access, Orphan Drugs, pricing, R&D, Regulatory | Also tagged , , , , | Leave a comment
  • Categories

  • Meta